Clinical Trial Update: Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System [Phase 3]

View source ↗

Summary

Phase 3 study evaluating discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia and the impact on the immune system.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Tyrosine kinase inhibitors

Snippet

Sponsor: Poitiers University Hospital | Conditions: Tyrosine Kinase Inhibitors, Chronic Myeloid Leukemia | Phase 3 | Status: RECRUITING